Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Drug Type
- Biotech
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Locally Advanced Intrahepatic CholangiocarcinomaMetastatic Intrahepatic CholangiocarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04708067
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
- Conditions
- SarcomasMelanomasGerm Cell TumorsEpithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)Pulmonary Metastases
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04648826
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
- Conditions
- Cancer Of ProstateProstate Neoplasms
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT04633252
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
- Conditions
- Solid TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT04574583
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
- Conditions
- Stage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Resectable Lung Non-Small Cell CarcinomaStage IIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8
- Interventions
- Procedure: Therapeutic Conventional Surgery
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT04560686
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 25
- Registration Number
- NCT04551950
- Locations
- 🇺🇸
Stanford Health Care Hospital & Clinics, Stanford, California, United States
🇪🇸Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona, Spain
🇯🇵Osaka International Cancer Institute, Osaka-shi, Japan
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 11
- Registration Number
- NCT04489940
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Medical Oncology Hematology Consultants, PA, Helen F. Graham Cancer Center, Suite 3400, Newark, Delaware, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
- Conditions
- Oesophageal CancerCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 49
- Registration Number
- NCT04481256
- Locations
- 🇳🇱
Academic Medical Center, Medical Oncology, Amsterdam, Netherlands
First in Human Study of M6223
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-12-08
- Target Recruit Count
- 58
- Registration Number
- NCT04457778
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
- Conditions
- Oropharyngeal CancerCervical CancerHPV Positive CancerAnal CancerVulvar, Vaginal, Penile, Rectal Cancer
- Interventions
- Biological: PRGN-2009 (Phase II)Biological: PRGN-2009 (Phase I)Diagnostic Test: MRIDiagnostic Test: Bone scanDiagnostic Test: CT scanDiagnostic Test: Brain CTDiagnostic Test: Brain MRIProcedure: Biopsy (Phase I)Procedure: Biopsy (Phase II)
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT04432597
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.